https://www.tadeclinicagem.com.br/guia/?utm_source=whatsapp&utm_medium=social&utm_term=&utm_content=&utm_campaign=Guia-blackfriday&utm_source_platform=&utm_creative_format=&utm_marketing_tactic=🎁 30 dias sem pagar nada. E sem compromisso. Se fizer sentido pra você, continua.👩‍⚕️ Mais de 7.000 médicos já confiam no Guia TdC para se manterem atualizados de forma leve, prática e acessível.⚡ Atualize-se de onde estiver, com uma consulta rápida, confiável e feita pra rotina médica real.📍 Resumos em texto e em áudio das principais publicações médicas📖 +400 artigos destrinchados já disponíveis🆕 3 novos conteúdos toda semana🔁 Revisões mensais de temas sugeridos por assinantes🩺 Casos clínicos comentados🎯 +1.500 flashcards para revisar quando quiser Guia TdC: o jeito inteligente de se manter em dia com a Medicina.🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨Iago, Guilherme e Ingrid discutem 7 armadilhas do uso de DOACs!Referências:1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368:699-708.2. Bikdeli B, Tajrishi FZ, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA cardiology.3. Weitz JI, Lensing AW, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MC. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine. 2017 Mar 30;376(13):1211-22.4. Eikelboom JW, Bhatt DL, Fox KA, Bosch J, Connolly SJ, Anand SS, Avezum A, Berkowitz SD, Branch KR, Dagenais GR, Félix C. Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. Journal of the American College of Cardiology. 2021 Jul 6;78(1):14-23.5. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine. 2017 Oct 5;377(14):1319-30.6. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. American journal of hematology. 2019 Jun;94(6):697-709.7. David A Garcia, Mark Crowther. Management of bleeding in patients receiving direct oralanticoagulants. Acesso em uptodate.com outubro/228. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood, The Journal of the American Society of Hematology. 2014 Aug 14;124(7):1020-8.9. Trujillo T, Dobesh PP. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs. 2014 Sep;74(14):1587-603.10. Martin KA, Lee CR, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. The American journal of medicine. 2017 May 1;130(5):517-24.11. Chen A, Stecker E, A. Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. Journal of the American Heart Association. 2020 Jul 7;9(13):e017559.